<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630393</url>
  </required_header>
  <id_info>
    <org_study_id>1306218</org_study_id>
    <nct_id>NCT03630393</nct_id>
  </id_info>
  <brief_title>Ultralow Versus Standard Pneumoperitoneum Pressure</brief_title>
  <acronym>Ultralow</acronym>
  <official_title>Randomized Study of Ultralow Versus Standard Pneumoperitoneum Pressure During Robotic Prostatectomy Using the AirSealÂ® Insufflation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OhioHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ConMed Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OhioHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to compare insufflation pressures during robotic assisted laparoscopic
      prostatectomy (RALP). Standard pressure is typically 15 mmHg, while in a previous study the
      investigators determined that 6 mmHg is possible routinely. Therefore, the investigators plan
      to compare the clinical outcomes of participants at a pneumoperitoneal pressure of 15 versus
      6 mmHg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators to examine the impact of low pressure during robotic assisted laparoscopic
      prostatectomy (RALP) with the intention of identifying whether lower pressures might benefit
      participants. The investigators hypothesize that a low insufflation pressure may provide an
      improvement in postoperative pain and abdominal distension in addition to potential
      physiologic benefits, and that these factors might then allow a shorter hospital stay. The
      investigators previously initiated a protocol in September of 2016 (IRB# 1066864) to perform
      RALPs at an insufflation pressure of 6 mmHg with the intention of increasing the pressure as
      needed on an individual participant level. In order to determine whether this might allow
      earlier discharge when successful, the investigators began allowing for same-day discharge in
      participants meeting appropriate criteria. Having now demonstrated feasibility in over 300
      consecutive participants using this ultralow pneumoperitoneum protocol, the investigators now
      plan to conduct a randomized trial to compare a pressure of 6 mmHg with participants having
      RALP at a standard pressure of 15 mmHg to determine whether there is a true benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain medication use</measure>
    <time_frame>Through 1 week postoperatively</time_frame>
    <description>Morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain scores</measure>
    <time_frame>Through discharge postoperatively</time_frame>
    <description>Pain scores on a 0-10 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative ventilation</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Average tidal volume (ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pressure 6 mmHg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pneumoperitoneum Pressure 6 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pressure 15 mmHg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pneumoperitoneum Pressure 15 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pneumoperitoneum Pressure 6 mmHg</intervention_name>
    <description>A pneumoperitoneum insufflation pressure of 6 mmHg will be used during RALP.</description>
    <arm_group_label>Pressure 6 mmHg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pneumoperitoneum Pressure 15 mmHg</intervention_name>
    <description>A pneumoperitoneum insufflation pressure of 15 mmHg will be used during RALP.</description>
    <arm_group_label>Pressure 15 mmHg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older

          2. Diagnosed with prostate cancer

          3. Electing to undergo robotic assisted laparoscopic prostatectomy (RALP)

        Exclusion Criteria:

          1. Age &lt; 18

          2. Emergency surgery

          3. Patients with a significant preoperative dependence on narcotic medications

          4. Unable to give informed consent

          5. Dementia, history of dementia, or other significant mental impairment that would, in
             the opinion of the investigator, impede patient self-reporting

          6. Persons participating in any other research study involving an investigational drug or
             device or investigational surgical procedure that could interfere with the physiologic
             parameters being collected (for example, a study evaluating different anesthesia
             regimens that could confound study results)

          7. Non-English-speaking or reading
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males with prostate cancer who are eligible and electing to undergo robotic assisted laparoscopic prostatectomy (RALP)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronney Abaza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OhioHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Chervin</last_name>
    <phone>614-544-8430</phone>
    <email>deborah.chervin@ohiohealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Rush</last_name>
    <phone>614-566-1250</phone>
    <email>laura.rush@ohiohealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dublin Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Chervin</last_name>
      <phone>614-544-8430</phone>
      <email>deborah.chervin@ohiohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Rush</last_name>
      <phone>614-566-1250</phone>
      <email>laura.rush@ohiohealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronney Abaza, MD,FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OhioHealth</investigator_affiliation>
    <investigator_full_name>Ronney Abaza</investigator_full_name>
    <investigator_title>Robotic Urologic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Prostatectomy</keyword>
  <keyword>Robotic</keyword>
  <keyword>Urology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumoperitoneum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

